Compare FOXF & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOXF | MLTX |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 734.7M | 863.0M |
| IPO Year | 2013 | 2020 |
| Metric | FOXF | MLTX |
|---|---|---|
| Price | $17.81 | $11.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 15 |
| Target Price | $18.33 | ★ $28.54 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,467,321,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.27 | N/A |
| 52 Week Low | $13.08 | $9.46 |
| 52 Week High | $22.09 | $23.29 |
| Indicator | FOXF | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.92 | 48.60 |
| Support Level | $17.50 | $9.73 |
| Resistance Level | $18.78 | $13.51 |
| Average True Range (ATR) | 0.87 | 0.85 |
| MACD | 0.34 | 0.08 |
| Stochastic Oscillator | 87.30 | 48.27 |
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World. The company operates in three segments: Powered Vehicles Group, Aftermarket Applications Group, and Specialty Sports Group, of which it derives maximum revenue from Specialty Sports Group segment.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.